How does budesonide delayed-release capsules work?

Budesonide delayed-release capsules are an innovative oral sustained-release corticosteroid capsule specifically developed to reduce inflammation and loss of kidney function in adult patients with primary immunoglobulin A nephropathy (IgAN) who are at risk for disease progression. As a B cell immunomodulator, it uniquely targets the core cause of IgAN - the production of pathogenic galactose-deficient IgA1 antibodies, which play a key role in the pathogenesis of IgAN.

In December 2021, budesonide delayed-release capsules received accelerated approval from the FDA, marking an important breakthrough in the field of IgAN treatment. This approval is based on excellent results from Part A of the pivotal Phase 3 study of NeflgArd. This study is an ongoing randomized, double-blind, placebo-controlled, multi-center trial designed to comprehensively evaluate the efficacy and safety of budesonide delayed-release capsules (16 mg daily) versus placebo in adult patients with primary IgAN. The primary objective of Part A of the study was successfully met, which was to achieve a statistically significant reduction in urinary protein to creatinine ratio (UPCR), or proteinuria, in patients treated with budesonide delayed-release capsules for 9 months compared with placebo. Specifically, at 9 months, the UPCR of patients taking budesonide delayed-release capsules plus a renin-angiotensin system inhibitor (RASi) (n=97) decreased by 34% from baseline, while the UPCR of patients taking RASi alone (n=102) only decreased by 5%, with a difference of 31% between the two groups.

Subsequently, in December 2023, budesonide delayed-release capsules received full approval from the US FDA, becoming the first treatment method to significantly reduce the loss of renal function in IgAN. This achievement is based on solid evidence of its long-term efficacy and safety. In a two-year study, patients were randomly divided into two groups: one group received budesonide delayed-release capsules plus optimized RASi treatment, and the other group received placebo plus optimized RASi treatment. After nine months of treatment and 15 months of follow-up, the study showed that the decline in estimated glomerular filtration rate (eGFR) was significantly smaller in the budesonide delayed-release capsule group compared with the placebo group. Specifically, at 2 years, the eGFR of the placebo group decreased by 12.0 mL/min/1.73 m², while the eGFR of the budesonide delayed-release capsule group only decreased by 6.11 mL/min/1.73 m².

The efficacy of budesonide delayed-release capsules is not only reflected in its ability to significantly reduce proteinuria and delay the deterioration of renal function, but may also have a positive impact on patients' quality of life. By precisely targeting the pathological mechanism of IgAN, it provides patients with a more effective, safe and well-tolerated treatment option.

In summary, budesonide delayed-release capsules, as an innovative B cell immunomodulator, have demonstrated significant efficacy in the treatment of adult patients with primary IgAN who are at risk of disease progression. It effectively reduces inflammation and loss of kidney function in patients by reducing the production of pathogenic galactose-deficient IgA1 antibodies. Long-term research data shows that budesonide delayed-release capsules can significantly reduce proteinuria, delay the deterioration of renal function, and are expected to improve patients' quality of life.

Reference materials:https://www.drugs.com/history/tarpeyo.html